Posts Tagged ‘Vanda’


Novartis: huge punitive fine in discrimination case. $250 million game-changing dollars.

FDA to the public – let’s talk more. Or, tell us more about what we should tell you.

GSK and more Avandia flak. This story will never end, it seems.

Pfizer and multiple corporate cultures. An interesting interview at Forbes magazine.

The Manual of Clinical Psychopharmacology gives a raspberry to the Vanda/Novartis schizophrenia drug Fanapt.


Software training. The Impactiviti partner network has the providers you need for training on software systems. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.


Good advice for all situations, including business: Give them your heart, then your head. From my friend Drew McLellan.


Visual treat. The stunning colors of Glacier National Park. I visited there once, years ago – it really is magnificent! And – Slow Motion Gum And Gelatin. Cooler than you might think (quick video).


Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)



Read Full Post »

This will probably be the last Top Three post for about a week or so, as I head out to Chicago for the SPBT (Society of Pharmaceutical and Biotech Trainers) conference. And there’s a bit of backlog today, so here goes – more than three!

Acorda shares jump after its experimental MS pill gets a priority review notice from FDA. Oral MS treatments are going to be big news over the next year…

Vanda gets approval for its schizophrenia drug. And, as is typical of atypicals, a black box warning.

Roche‘s Avastin cleared for brain cancer.

Solvay receives FDA approval for pancreas drug Creon.

Drug-coated stents – safety verified, and better at keeping arteries open.

Plavix and Purple don’t mix?

An interesting discussion of marketing tactics (pay-for-non-performance) in Europe over osteo drugs, and the upcoming Novartis/Amgen tussle in that area.

Credibility on the commercial side of pharma marketing (Vioxx): Not. Not.


Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »